Public Companies
XPhyto Files Patent Application for Library of Novel Psychedelic Compounds
XPhyto Therapeutics Corp. (CSE:XPHY | OTCQB:XPHYF | FSE:4XT) is pleased to report that it has filed a patent application for a significant library of…
XPhyto Therapeutics Corp. (CSE:XPHY | OTCQB:XPHYF | FSE:4XT) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties.
The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate (OUD), and cocaine addiction, alcoholism (AUD), post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Novel methods of administration might be applied for dosing to further optimize therapeutic outcomes. This significant library of psychedelic derived molecules secures XPhyto a platform technology to which variations of the molecules can be applied to various indications as noted. The potential applications are subject to the requisite clinical and regulatory commercialization processes.
The global psychedelic drugs market is expected to gain significant market growth in the forecast period from 2022 to 2029. Data Bridge Market Research reports that the market is growing with a CAGR of 13.3% in the forecast period from 2022 to 2029 and is expected to reach USD 6,401.95 million by 2029 from USD 2,386.72 million in 2021.
Related development work has been carried out as part of an ongoing exclusive psychedelic R&D partnership with Applied Pharmaceutical Innovation. XPhyto is pursuing a multi-strategic approach to psychedelic medicine including drug synthesis, drug delivery and novel psychedelic analogue engineering. Applied is a not-for-profit institution at the University of Alberta created to support translational drug development for industry and innovators. The intellectual property is retained 100% by XPhyto.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
-
Psilocybin1 week ago
Tulum vs. Oaxaca: The Tale of 2 Psychedelic Cities
-
Psychedelics5 days ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week ago
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Psychedelics5 days ago
All About the New Ketamine Trial at the University of Otago
-
Law & Regulation1 week ago
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
-
Psychedelics1 week ago
Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research
-
Psychedelics5 days ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
-
Law & Regulation1 week ago
Synaptogenix increases psilocybin stake with PsygaBio